FIG 1.

CONSORT diagram. (*) Did not receive an assignment because of ineligible histology: colorectal cancer (n = 44), melanoma (n = 14), papillary thyroid cancer (n = 9), and non–small-cell lung cancer (n = 1); (†) reasons not enrolled after receiving an assignment: central screening cohort: death (n = 2), patient refusal (n = 1), prior treatment (n = 2), disease progression (n = 1), BRAF inhibitor started before assignment (n = 2), inadequate organ/marrow function (n = 2), not able to swallow tablets (n = 1), no longer met master protocol eligibility (n = 1), and unknown (n = 2); outside assay cohort: deteriorating performance status (n = 1) and unknown (n = 1).